[144] CareDx, Inc. SEC Filing
Rhea-AI Filing Summary
CareDx, Inc. insider Jeffrey Novack has filed a Form 144 notice to sell company stock. The filing covers a proposed sale of 4,441 shares of CareDx common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $90,685.22 and 51,432,639 shares of common stock outstanding.
The shares to be sold were acquired on 02/01/2026 via 2,591 restricted stock units and 1,850 performance stock units from the issuer, both settled on 02/01/2026. Over the past three months, Form 144 discloses additional 10b5-1 sales for Jeffrey Novack totaling 7,293 shares on 12/04/2025 and 2,688 shares on 11/07/2025, with gross proceeds of $139,804.74 and $41,722.87, respectively.
Positive
- None.
Negative
- None.
Insights
Routine Form 144 shows modest planned sales under Rule 10b5-1.
The notice details a planned sale of 4,441 CareDx common shares with an indicated market value of $90,685.22, against 51,432,639 shares outstanding. The securities come from recently vested restricted stock units and performance stock units dated 02/01/2026.
The document also lists prior three‑month 10b5‑1 sales of 7,293 and 2,688 shares, with gross proceeds of $139,804.74 and $41,722.87. The signatory represents they are not aware of undisclosed material adverse information, consistent with Rule 144 and Rule 10b5‑1 requirements.
FAQ
What does the CareDx (CDNA) Form 144 filing by Jeffrey Novack disclose?
What prior CareDx (CDNA) stock sales are reported in the last three months?
Does the CareDx (CDNA) Form 144 mention Rule 10b5-1 trading plans?
AI-generated analysis. How Rhea-AI works. Not financial advice.